Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Trending Stocks: Davita, Nordstrom, AbbVie, and More

Despite the fact that the polls are narrowing and November 8 is just over a week away, the markets are rather calm, as all three indexes are moderately in the green.

Among the stocks that are capturing investors’ attention today are Nordstrom, Inc. (NYSE:JWN), AbbVie Inc (NYSE:ABBV), AutoNation, Inc. (NYSE:AN), Deere & Company (NYSE:DE), and Davita Inc (NYSE:DVA). Let’s examine the various reasons causing the five stocks to trend and analyze how hedge funds have been trading the five stocks using the latest 13F data.

Our research determined that following the small-cap stocks that hedge funds are collectively bullish on can help a smaller investor to beat the S&P 500 by around 95 basis points per month (see the details).

stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart


Nordstrom, Inc. (NYSE:JWN) is 0.8% in the red after Paul Trussell of Deutsche Bank downgraded the stock to ‘Hold’ from ‘Buy’ and trimmed his price target on it to $56 from $57, citing the luxury retailer’s rather full valuation. Shares of Nordstrom have rallied by over 45% since late-June, and the stock doesn’t look cheap without more sales growth. John W. Rogers‘ Ariel Investments owned 1.24 million shares of Nordstrom, Inc. (NYSE:JWN) on June 30, up by 9% from its stake on March 31.

Follow Nordstrom Inc (NYSE:JWN)
Trade (NYSE:JWN) Now!

AbbVie Inc (NYSE:ABBV) shares are down by 2% after Vamil Divan of Credit Suisse downgraded the stock to ‘Neutral’ from ‘Outperform’ and trimmed his price target to $60 per share from the previous mark of $70. Divan sees limited upside pipeline catalysts in the near-term and is rather concerned about Humira’s success given the increased attention to pricing transparency and the tougher payer environment. Of the 749 hedge funds that we track which filed 13Fs for the June quarter, 57 owned $4.77 billion in AbbVie Inc (NYSE:ABBV) positions on June 30, down from 65 funds holding $5.28 billion in positions on March 31.

Follow Abbvie Inc. (NYSE:ABBV)
Trade (NYSE:ABBV) Now!

On the next page we’ll take a closer look at the latest on AutoNation, Deere & Company, and Davita.